Telitacicept
- Generic Name
- Telitacicept
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2136630-26-5
- Unique Ingredient Identifier
- 1FHM3D7Z49
- Indication
用于治疗系统性红斑狼疮（SLE）、类风湿性关节炎等多种自身免疫疾病。
小知识：SLE症状表现多样，如面部出现红斑、关节肿痛、对光过敏、口腔溃疡等，随着病情的进展可导致肾脏、心血管等全身多系统、多器官的不可逆损害，严重威胁生命。目前，我国SLE患病人数超过100万，居全球之首，且多发于15-45岁的年轻女性，女性患病率为男性的10.1倍。
- Associated Conditions
- -
- Associated Therapies
- -
Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Guanmin Gao
- Target Recruit Count
- 64
- Registration Number
- NCT05929248
Efficacy and Safety of Telitacicept in Early SLE
- Conditions
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT05899907
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, China
🇨🇳First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
A Study of Telitacicept in Patients With Primary IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 308
- Registration Number
- NCT05799287
- Locations
- 🇨🇳
Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University Shougang Hospital, Beijing, Beijing, China
A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05687526
- Locations
- 🇨🇳
Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Chengdu Women's & Children's Central Hospital, Chengdu, Sichuan, China
Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 80
- Registration Number
- NCT05644210
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
Study of Telitacicept in Patients With Refractory IgA Nephropathy
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2023-02-24
- Target Recruit Count
- 40
- Registration Number
- NCT05596708
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study
- Conditions
- Interventions
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2022-10-20
- Target Recruit Count
- 60
- Registration Number
- NCT05588830
Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Liu Tian
- Target Recruit Count
- 60
- Registration Number
- NCT05339217
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT05306574
- Locations
- 🇬🇹
Guatemala site, Guatemala, Guatemala
🇺🇸Orange Site, Orange, California, United States
🇲🇺Quatre Bornes Site, Quatre Bornes, Mauritius
Telitacicept in Primary APS Patients
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05078710
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.